higher. Despite this, disease due to S. Paratyphi A, B, or C is poorly characterized, with few data regarding risk factors, disease severity, outcome, or antibacterial susceptibilities.
The incidence of enteric fever correlates strongly with poor sanitation and limited access to clean drinking water. Nepal is a developing country, where the disease is endemic and remains the most common clinical and blood culture-confirmed diagnosis among patients with febrile illness [2] . The burden of infection is huge-in Patan Hospital (Kathmandu) alone, we see 12500 suspected cases each year, and the proportion of cases due to S. Paratyphi A increased from 21.7% during 1993-1997 to 33.8% during 1998-2003. This is consistent with reports from elsewhere in Asia that detail an increasing incidence of S. Paratyphi A infection, which is now responsible for up to 15% cases of enteric fever in India and 1% of cases in The Philippines [3] [4] [5] [6] [7] .
S. Paratyphi A is thought to cause milder disease than does S. Typhi, with predominantly gastrointestinal symptoms [8, 9] . Although this is probably true in the case of S. Paratyphi B infection, there are insufficient data to draw this conclusion for S. Paratyphi A, with a lack of adequately sized clinical studies [10] . The increasing incidence of this infection underlines the need to better characterize its clinical phenotype. The death rate for hospitalized patients with S. Typhi infection varies from 2% in Pakistan and Vietnam to 30%-40% in Indonesia and Papua New Guinea [11] . There are few data from which to generate death or complication rates for S. Paratyphi A infection.
The most important factor in preventing death due to enteric fever is the timely introduction of treatment with effective antibacterials. The emergence of antibacterial resistance has been rapid throughout the treatment history of typhoid and was first reported in 1950 after the introduction of chloramphenicol 2 years previously. In the 1980s and 1990s, S. Typhi developed simultaneous resistance to all first-line drugs, notably chloramphenicol, amoxicillin, and trimethoprim-sulfamethoxazole (TMP-SMZ), encoded on a single plasmid [11] . These multidrug-resistant strains are now widespread, and fluoroquinolones have largely replaced other agents as the drugs of choice. Emerging resistance to fluoroquinolones has been a major setback [12] . In Nepal, the extent of quinolone and fluoroquinolone resistance is uncertain, because most laboratories do not have the facilities for susceptibility testing. Over recent years, we have noticed an increased rate of poor response to firstline treatment (ofloxacin) in patients with enteric fever in our hospital. After fluoroquinolones, treatment choices are limited but include expensive alternatives, such as third-generation cephalosporins or azithromycin [13] [14] [15] [16] [17] [18] [19] . Few studies have been done on antibacterial susceptibility patterns of S. Paratyphi A, because it is less frequently the cause of enteric fever. There have been sporadic reports on the growing numbers of drugresistant S. Paratyphi A in India and Europe [5, 20] . Finally, although reasonably effective vaccines exist for S. Typhi, there are no licensed vaccines available for S. Paratyphi A.
We designed a prospective, descriptive study of enteric fever at Patan Hospital to address the issues regarding etiology, clinical phenotype (according to infecting organism), and antibacterial susceptibilities of infecting isolates.
MATERIALS AND METHODS
Setting. Kathmandu, the largest city in Nepal, has a population of 1.5 million. Patan Hospital is a 318-bed mission/ government hospital providing emergency and elective outpatient and inpatient services. There are 300,000 outpatient visits, 35,000 emergency visits, and 15,000 admissions annually. The vast majority of patients with enteric fever are treated as outpatients.
Patients. The study was conducted from January to August 2004. Ethics approval was obtained from Patan Hospital. All patients of any age who were suspected of having enteric fever and who attended the outpatient clinics or emergency department or who were admitted for treatment were referred to the study physician. After obtaining informed consent, the study physician interviewed and examined each patient, recording the data on a standardized form. Other than culture of blood specimens, laboratory investigations and treatment choice were left to the discretion of the attending physician. Information collected included demographic details, symptoms, physical findings, contact with other cases of enteric fever, recent antibacterial use, and source and use of water purification methods in the patient's home. The study physician also reviewed all blood culture requests and results, so that patients who might have had enteric fever but for some reason had not been referred could be identified and included in the study. For analysis, a patient with enteric fever was defined as any patient with a blood culture positive for S. serovar Typhi or serovar Paratyphi A, B, or C.
Microbiological methods. Blood was inoculated into tryptone soya broth at 37ЊC, with daily examination for growth over 1 week. Bacteria were identified using standard microbiological tests. Specific antisera distinguished S. Typhi and S. Paratyphi A, B, or C (Murex Diagnostics). Antibacterial susceptibilities were determined at the time of isolation using the modified Kirby-Bauer disk diffusion method, and results were interpreted on the basis of the guidelines for Enterobacteriaceae of the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) [21] . The antibacterials tested were nalidixic acid, ciprofloxacin, ofloxacin, amoxicillin, chloramphenicol, TMP-SMZ, and ceftriaxone (Himedia Laboratory).
Isolates were stored on brain-heart infusion/glycerol broth at Ϫ20ЊC. MICs were determined for 50 strains of both serotypes using the Etest (AB Biodisk) for nalidixic acid (range of antibacterial concentration in testing, 0.16-256 mg/mL), ciprofloxacin (0.002-32 mg/mL), ofloxacin (0.002-32 mg/mL), gatifloxacin (0.002-32 mg/mL), chloramphenicol (0.16-256 mg/ mL), and ceftriaxone (0.002-32 mg/mL).
Data analysis. Statistical analysis was performed using SPSS software for Windows, version 10.0 (SPSS). For categorical or dichotomized parameters, proportions between groups were compared using the x 2 or Fisher's exact test. For continuous parameters, the Mann-Whitney U test was used. Forward stepwise logistic regression was used to determine significant variables independently associated with either infection. All variables in the univariate analysis with a P value !.15 were in-cluded in the regression analysis. The coefficients of variables identified were used to develop a simple diagnostic rule. The predicted score scale was tested against the observed diagnostic outcome to check for the diagnostic rule's sensitivity and specificity. The area under the receiver operator characteristic curve of the diagnostic score was used to evaluate the usefulness of the diagnostic rule in distinguishing the 2 infections. For analysis, when MICs for an isolate were greater than the upper limit measurable by Etest, the value was assumed to be double the maximum measurable.
RESULTS
During the study period, 174,380 patients visited the hospital, and 7236 blood cultures were performed. Of these, 2535 were ordered because of the suspicion of enteric fever. S. enterica was isolated from blood of 609 (24%) patients who were suspected of having enteric fever (409 S. Typhi isolates [67%] and 200 S. Paratyphi A isolates [33%]). There were no S. Paratyphi B or C isolates. One patient was excluded from analysis because the infection was believed to represent a relapse.
Demographic data, history, and examination findings are presented in table 1. There were no significant differences between the 2 patient populations with regard to sex, socioeconomic class, or ethnicity. Most patients were Kathmandu valley inhabitants. Only 2 patients in the study had ever received typhoid vaccination.
Other than municipality-supplied tap water, 25% of patients also used local water resources, most commonly stone spout (13%-14%); 53% of patients drank untreated water. There were no discernible differences in water supply or use of additional water purification methods between patients with infection due to S. Typhi or S. Paratyphi A.
Although there was no difference in the overall rate of antibacterial use before hospital presentation between groups (17.6% with S. Typhi infection vs. 22.0% with S. Paratyphi A infection), patients with infection due to S. Paratyphi A were more likely to have received a quinolone (13% vs. 5.9%;
). P ! .01 There were no statistically significant differences in individual symptoms between patients with infection due to S. Typhi or S. Paratyphi A. The median duration of illness at presentation was 5 days for S. Paratyphi A and 4 days for S. Typhi (P p ). The most common presenting complaints were fever and .05 headache (for S. Paratyphi A, 99% and 83%; for S. Typhi, 96% and 79%, respectively). Frequent other symptoms included anorexia, abdominal pain, chills, and cough. Diarrhea was more common than constipation. Physical findings included coated tongue (50.6%-55.8%), splenomegaly (5.2%-6.1%), and abdominal tenderness (4.5%-4.7%). The statistically significant differences in pulse rate and temperature between groups were so small as not to be clinically important. More patients with infection with S. Typhi had wheezing on chest auscultation (3.4% vs. 0.5%;
). P p .03 There was no difference in overall rate of complications for infection due to S. Typhi compared with that due to S. Paratyphi A (5.65% vs. 3.5%;
). Hepatitis with clinical jaun-P p .28 dice was observed in 6 (1.47%) of patients with S. Typhi infection and 3 (1.5%) with S. Paratyphi A infection. Three patients with infection due to S. Typhi had neurological symptoms consistent with enteric encephalopathy. Gastrointestinal bleeding (melena) was observed in 2 patients with S. Paratyphi A infection and in 1 patient with S. Typhi infection. Thirtyfive patients were admitted for inpatient treatment: 26 (6.4%) had infection due to S. Typhi, and 6 (3%) had infection due to S. Paratyphi A (
). There were no fatalities. P p .08 Laboratory findings are shown in table 2. Stepwise multiple regression analysis found a higher monocyte count to be independently associated with S. Paratyphi A infection (adjusted OR, 1.33; 95% CI, 1.05-1.69;
). No other variables were P p .02 independently predictive of either infection. We tested the usefulness of the monocyte count in determining the etiology of enteric fever using a receiver operator characteristic curve analysis. A cutoff value for monocyte count of 2.5% gave a test specificity of 83.4% but a sensitivity of only 39.7% (positive and negative predictive values, 56.25% and 71.5%, respectively). The analysis was repeated excluding the laboratory parameters. This increased the sample size for the model from 113 patients to 509 patients (165 with infection due to S. Paratyphi A and 344 with infection due to S. Typhi). Two variables were important: age (OR, 1.04; 95% CI, 1.01-1.06;
) and pres-P ! .001 ence of wheeze (OR, 0.14; 95% CI, 0.02-1.13;
). The P p .065 subsequent clinical diagnostic rule could not reliably distinguish the 2 infections, with a sensitivity of 81%, a specificity of 34%, a positive predictive value of 37%, and a negative predictive value of 79%. Table 3 contains results of disk diffusion antibacterial susceptibility testing. S. Paratyphi A was significantly more likely to be resistant to nalidixic acid and ofloxacin than was S. Typhi and significantly more likely to have intermediate resistance to ofloxacin (28.7% vs. 1.8%; OR, 16.4; 95% CI, 6.9-40.8; P ! ). There was no difference in the prevalence of ciprofloxacin .001 resistance between S. Paratyphi A and S. Typhi, but S. Paratyphi A was significantly more likely to have reduced susceptibility (39.4% vs. 8.2%; OR, 7.4; 95% CI, 4.6-12.0;
). Overall P ! .001 resistance rates for amoxicillin, chloramphenicol, and TMP-SMZ were low, with no significant differences. Five S. Typhi isolates and 3 S. Paratyphi A isolates were resistant to amoxicillin, TMP-SMZ, and chloramphenicol. Ceftriaxone resistance was detected in 1 S. Paratyphi A isolate and was not found in any S. Typhi isolate.
Etest was used to determine ceftriaxone, nalidixic acid, ciprofloxacin, ofloxacin, gatifloxacin, and chloramphenicol MICs 
DISCUSSION
This is the largest descriptive study of enteric fever published since 1963 and the largest-ever prospective study [10] . The results are significant for 4 reasons. First, the study demonstrates that both S. Typhi and S. Paratyphi A infections can be highly prevalent at the same time in the same population. Second, the disease phenotype for the 2 infections is identicalwe found no difference in disease presentation or complication rate between infections due to S. Paratyphi A and S. Typhi. This is contrary to classic teaching that S. Paratyphi A causes milder disease than does S. Typhi [8] . The inability to develop a practicable diagnostic rule from the analyzed parameters using clinical data or clinical combined with laboratory values underlines the similarity of the disease phenotype of these 2 infections. Third, we found that, although antibacterial resistance was common among S. Typhi isolates, S. Paratyphi A isolates were even more likely to have resistance to drugs (50.5% vs. 75.25% for nalidixic acid). Finally, MICs of all antibacterials tested for S. Paratyphi A strains were significantly higher than those for S. Typhi strains, including those antibacterials commonly in use and those used in the past.
Strategies to control enteric fever include improving water supply and sanitation, vaccination, and antibacterial therapy. The belief that S. Paratyphi A produces milder disease, which our study suggests is mistaken, has led to its neglect as an important pathogen. Consequently, there is no effective vaccination, and strategies to address S. Paratyphi A infection remain improvement in public health, provision of clean drinking water, and drug therapy.
The coexistence of these 2 pathogens in the same population is worrying. The 2 widely available, practicable, and safe S. Typhi vaccines (Vi polysaccharide vaccine and Ty21a vaccine) confer no protection against S. Paratyphi A. Asia is seeing an increase in the prevalence of S. Paratyphi A. The ecological interplay, if any, between S. Paratyphi A and S. Typhi is not understood, but one concern is that any benefit gained through effective mass vaccination against S. Typhi may be negated by an increase in enteric fever due to drug-resistant S. Paratyphi A. This hypothesis needs to be tested. Of note, a small study from Nepal suggested an increase in the incidence of S. Paratyphi A infection among foreigners receiving typhoid vaccination [22] . However, after mass vaccination of school children using heat-inactivated typhoid vaccine in Thailand, although the ratio between the incidence of infection with S. Paratyphi A and S. Typhi increased, there was no actual increase in S. Paratyphi A infections [23] .
Contrary to recent data from Indonesia, we found no differences in risk factors for S. Paratyphi A or S. Typhi infection [24] . Additional research in this area is needed and may lead to insights regarding the differences in antibacterial susceptibility between the 2 pathogens.
The emergence of antibacterial resistance in S. Typhi is well documented and has been a major setback; there is a real pros- pect that untreatable typhoid will emerge [11, 25] . This study suggests that the same will be true for S. Paratyphi A-and perhaps sooner than for S. Typhi. There are few data available regarding the antibacterial susceptibilities of S. Paratyphi A strains, and the first case of high-level resistance to ciprofloxacin was described in the published literature in 2004 [21, 26] . The higher MICs for the S. Paratyphi A isolates are particularly significant, given that evidence from both animal models and clinical studies suggests that the current Clinical and Laboratory Standards Institute breakpoints for S. enterica are too high and do not reliably predict clinical response [27] [28] [29] [30] . Patients infected with nalidixic acid-resistant isolates respond less well to fluoroquinolones, even when the isolates' MICs are within the susceptible range for fluoroquinolones [31, 32] . Treatment failures have been described for isolates with ciprofloxacin MICs as low as 0.125 mg/mL, and although there is perhaps not yet sufficient evidence to revise the break points to this level, 1 mg/ mL is used by some investigators [20] . A significant proportion of our isolates had MICs greater than this. New break points that relate to clinical outcome need to be defined for the fluoroquinolones for both S. Typhi and S. Paratyphi A. The presence of multidrug-resistant (plasmid-mediated) organisms within our population suggests that the reintroduction of amoxicillin, chloramphenicol, or TMP-SMZ as therapy would soon be met by widespread treatment failure. We found that all strains resistant to ciprofloxacin by Etest were also resistant to nalidixic acid, and nalidixic acid-resistant strains of S. Paratyphi A had a higher median MIC (0.75 mg/mL), suggesting that nalidixic acid susceptibility could also be used as an indicator of fluoroquinolone resistance (data not shown).
Clearly, the control of enteric fever needs more than effective antibacterial treatment. The relatively good rate of access to latrines in our population implies that, in addition to improving basic sanitation, education about safe drinking water and food preparation could be important in reducing the rate of enteric fever in Kathmandu. The difficulties in changing centuries-old practices, such as drinking from traditional unpurified water spouts, renowned for their flavor, mean that vaccination may play an important role in controlling this disease in indigenous populations as well as travelers. In the past 5 years, there have been increasing numbers of cases of enteric fever due to S. Paratyphi A in both of these groups [4, 5] .
Drug-resistant S. Paratyphi A threatens to become a disease of increasing Asian, and possibly global, significance. There is an urgent need to develop new interventions. S. Typhi vaccines are part of the public health strategy to control typhoid in parts of Asia, although the increasing incidence of S. Paratyphi A infections threatens to undermine their usefulness in reducing enteric fever [33] . Our experience suggests that S. Paratyphi A may pose as significant a public health risk as does S. Typhi, and in the face of the development of antibacterial resistance, the development of an effective vaccine should be a priority.
